Company Overview

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.

Concert applies its proprietary DCE Platform (deuterated chemical entity platform) to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including HIV/AIDS and renal disease, among others. In 2009, Concert's first patents were granted by the USPTO.

In June 2009, Concert announced a $1 billion strategic partnership with GlaxoSmithKline to develop and commercialize deuterium-containing drugs, including a protease inhibitor for the treatment of HIV.

Concert is a rapidly growing company based in Lexington, Massachusetts. The Company is led by an experienced management team and Board of Directors, and is supported by top-tier venture capitalists and leading institutional investors. Concert has raised >$110 million since its inception. Concert was co-founded by Richard Aldrich, Roger Tung and Christoph Westphal.

[ back to top ]